Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14873888 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL725752 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL20169646 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL16329660 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL15773944 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL1397641 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL16329771 | 1.00 | HIF1A (0.32) | HIF1A | |
| SCHEMBL16692019 | 0.97 | — | — | |
| SCHEMBL16329560 | 0.93 | — | — | |
| SCHEMBL23130636 | 0.86 | HIF1A (0.41) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654772-B1 | CYCLIC CRF ANTAGONIST PEPTIDES | SALK INST BIOLOGICAL STUDIES (US) | 2018-09-26 | — | — | EP | claimed |
| US-9035022-B2 | Cyclic CRF antagonist peptides | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-05-19 | — | — | US | claimed |
| US-20140024802-A1 | CYCLIC CRF ANTAGONIST PEPTIDES | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2014-01-23 | — | — | US | claimed |
| EP-2654772-A2 | CYCLIC CRF ANTAGONIST PEPTIDES | The Salk Institute for Biological Studies (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012088397-A2 | CYCLIC CRF ANTAGONIST PEPTIDES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-06-28 | — | — | WO | claimed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3134127-B1 | ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | RINAT NEUROSCIENCE CORP (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017174610-A1 | INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET | UNIVERSITE DE STRASBOURG (FR) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024802-A1 | CYCLIC CRF ANTAGONIST PEPTIDES | CRH, CRHBP, CRHR1 | HIF1A 1370/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | HIF1A 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.